Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
Daiwa analyst Narumi Nakagiri downgraded AbbVie (ABBV) to Neutral from Outperform with an $180 price target Don't Miss our Black Friday ...
Not knowing where these conversations will go, the show "allows us to enjoy the technology ...